CN1556828A - 具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物 - Google Patents
具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物 Download PDFInfo
- Publication number
- CN1556828A CN1556828A CNA038011050A CN03801105A CN1556828A CN 1556828 A CN1556828 A CN 1556828A CN A038011050 A CNA038011050 A CN A038011050A CN 03801105 A CN03801105 A CN 03801105A CN 1556828 A CN1556828 A CN 1556828A
- Authority
- CN
- China
- Prior art keywords
- derivative
- conjugate
- group
- hydroxyl
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 229920000642 polymer Polymers 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 10
- 229940079593 drug Drugs 0.000 claims abstract description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 claims description 96
- 239000002202 Polyethylene glycol Substances 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 239000001257 hydrogen Substances 0.000 claims description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 230000001681 protective effect Effects 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000010695 polyglycol Substances 0.000 claims description 15
- 229920000151 polyglycol Polymers 0.000 claims description 15
- -1 polypropylene morpholine Polymers 0.000 claims description 15
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 125000004185 ester group Chemical group 0.000 claims description 10
- 229940079322 interferon Drugs 0.000 claims description 10
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 9
- 108010050904 Interferons Proteins 0.000 claims description 9
- 102000014150 Interferons Human genes 0.000 claims description 9
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 9
- 150000001263 acyl chlorides Chemical class 0.000 claims description 9
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical class COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 claims description 8
- 239000005864 Sulphur Substances 0.000 claims description 8
- 239000011159 matrix material Substances 0.000 claims description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims description 8
- 229930012538 Paclitaxel Natural products 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 229960001592 paclitaxel Drugs 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 6
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 claims description 5
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000003054 catalyst Substances 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000006116 polymerization reaction Methods 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 3
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 229960003720 enoxolone Drugs 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 239000002777 nucleoside Substances 0.000 claims description 3
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229930013930 alkaloid Natural products 0.000 claims description 2
- 229910021529 ammonia Inorganic materials 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 150000002215 flavonoids Chemical class 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000003835 nucleoside group Chemical group 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 150000004053 quinones Chemical class 0.000 claims description 2
- 150000003505 terpenes Chemical class 0.000 claims description 2
- 235000007586 terpenes Nutrition 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229930182478 glucoside Natural products 0.000 claims 2
- 150000008131 glucosides Chemical class 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 241000050051 Chelone glabra Species 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182470 glycoside Natural products 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 229930015704 phenylpropanoid Natural products 0.000 claims 1
- 125000002456 taxol group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 42
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 38
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 23
- 238000001914 filtration Methods 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229920001427 mPEG Polymers 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 239000013049 sediment Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000002131 composite material Substances 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000006320 pegylation Effects 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 238000010533 azeotropic distillation Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 125000005909 ethyl alcohol group Chemical group 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- UWIULCYKVGIOPW-UHFFFAOYSA-N Glycolone Natural products CCOC1=C(CC=CC)C(=O)N(C)c2c(O)cccc12 UWIULCYKVGIOPW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- GRVPIHWKWIYXOM-DKWTVANSSA-N N[C@@H](C)C(=O)O.COC Chemical compound N[C@@H](C)C(=O)O.COC GRVPIHWKWIYXOM-DKWTVANSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- DDFGTVSLZJLQEV-UHFFFAOYSA-N [C](C1CCCCC1)C1CCCCC1 Chemical compound [C](C1CCCCC1)C1CCCCC1 DDFGTVSLZJLQEV-UHFFFAOYSA-N 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical class Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CZXGXYBOQYQXQD-UHFFFAOYSA-N methyl benzenesulfonate Chemical compound COS(=O)(=O)C1=CC=CC=C1 CZXGXYBOQYQXQD-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003541 multi-stage reaction Methods 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 229940106366 pegintron Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000010148 water-pollination Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims (1)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN02/00147 | 2002-03-13 | ||
CN0200147 | 2002-03-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1556828A true CN1556828A (zh) | 2004-12-22 |
CN1243779C CN1243779C (zh) | 2006-03-01 |
Family
ID=27792878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038011050A Expired - Lifetime CN1243779C (zh) | 2002-03-13 | 2003-03-12 | 具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物 |
Country Status (9)
Country | Link |
---|---|
US (3) | US8003089B2 (zh) |
EP (1) | EP1496076B1 (zh) |
JP (1) | JP4272537B2 (zh) |
CN (1) | CN1243779C (zh) |
AT (1) | ATE368066T1 (zh) |
AU (1) | AU2003221291A1 (zh) |
DE (1) | DE60315145T2 (zh) |
ES (1) | ES2291620T3 (zh) |
WO (1) | WO2003076490A1 (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052428A1 (fr) * | 2006-10-24 | 2008-05-08 | Beijing Jenkem Technology Co. Ltd | Procédé de preparation et conjugué avec molécule médicinale correspondante |
CN101636414B (zh) * | 2007-09-04 | 2012-02-15 | 厦门伯赛基因转录技术有限公司 | 聚乙二醇修饰的干扰素α2b及其制备方法和应用 |
WO2014114262A1 (zh) * | 2013-01-28 | 2014-07-31 | 天津键凯科技有限公司 | 水溶性聚合物-氨基酸寡肽-药物结合物及其制备方法和用途 |
CN104109235A (zh) * | 2014-05-30 | 2014-10-22 | 厦门赛诺邦格生物科技有限公司 | 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质 |
CN106750250A (zh) * | 2016-12-21 | 2017-05-31 | 沈阳化工大学 | 以氨基酸作为连接臂的聚乙二醇齐墩果酸衍生物及其制备方法和应用 |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
WO2018177055A1 (zh) * | 2017-03-30 | 2018-10-04 | 北京键凯科技股份有限公司 | 一种y型分支的亲水性聚合物羧酸衍生物的制备方法 |
CN108659227A (zh) * | 2017-03-30 | 2018-10-16 | 北京键凯科技股份有限公司 | 一种y型分支的亲水性聚合物羧酸衍生物的制备方法 |
CN109400868A (zh) * | 2018-11-30 | 2019-03-01 | 吉林化工学院 | 一种聚乙二醇单苯甲醚化合物的合成方法 |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10209822A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid |
DE10209821A1 (de) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Kopplung von Proteinen an ein modifiziertes Polysaccharid |
DE60315145T2 (de) | 2002-03-13 | 2008-04-30 | Beijing Jiankai Technology Co., Ltd. | Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff |
KR101174510B1 (ko) | 2002-09-11 | 2012-08-16 | 프레제니우스 카비 도이치란트 게엠베하 | 하이드록시알킬전분화 폴리펩티드, 특히 하이드록시알킬전분화 에리트로포이에틴 |
DE10326303A1 (de) * | 2003-06-11 | 2004-12-30 | Celares Gmbh | Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung |
WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
GB0329825D0 (en) * | 2003-12-23 | 2004-01-28 | Celltech R&D Ltd | Biological products |
EP2336192A1 (en) | 2004-03-11 | 2011-06-22 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
CA2606583C (en) * | 2005-05-20 | 2013-09-17 | Agency For Science, Technology And Research | Aldehyde conjugated flavonoid preparations |
US7858080B2 (en) | 2005-05-20 | 2010-12-28 | Agency For Science, Technology And Research | Aldehyde conjugated flavonoid preparations |
JP2009514814A (ja) * | 2005-10-21 | 2009-04-09 | シナジェバ・バイオファーマ・コーポレイション | グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質 |
US20080171696A1 (en) * | 2005-10-21 | 2008-07-17 | Avigenics, Inc. | Pharmacodynamically enhanced therapeutic proteins |
WO2007140282A1 (en) * | 2006-05-24 | 2007-12-06 | Peg Biosciences | Peg linker compounds and biologically active conjugates thereof |
CN101125207B (zh) * | 2006-11-14 | 2012-09-05 | 上海华谊生物技术有限公司 | 带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途 |
CN101835482A (zh) * | 2007-08-20 | 2010-09-15 | 安佐制药股份有限公司 | 含吡啶基二硫化物部分的聚合连接基 |
CN101636411B (zh) * | 2007-09-04 | 2013-01-09 | 厦门伯赛基因转录技术有限公司 | 聚乙二醇修饰的干扰素α2a及其制备方法和应用 |
EP2070950A1 (en) | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2236521A4 (en) * | 2007-12-29 | 2013-07-10 | Biosteed Gene Expression Tech Co Ltd | BY POLYETHYLENE GLYCOL OF Y-TYPE MODIFIED G-CSF AND METHOD FOR THE PRODUCTION AND USE THEREOF |
PL2272875T3 (pl) | 2008-04-03 | 2014-06-30 | Biosteed Gene Expression Tech Co Ltd | Hormon wzrostu modyfikowany dwuniciowym glikolem polietylenowym, sposoby otrzymywania i stosowania |
CN101701068B (zh) * | 2009-10-30 | 2011-09-21 | 北京化工大学 | 一种pH响应性的Y型药物输送材料及其制备方法 |
JP2011105792A (ja) * | 2009-11-12 | 2011-06-02 | Japan Science & Technology Agency | ブロックコポリマー、ブロックコポリマー−金属錯体複合体、及びそれを用いた中空構造体キャリア |
FR2953720B1 (fr) * | 2009-12-11 | 2012-05-11 | Oreal | Utilisation de derives de benzyloxy-ethylamines comme conservateur, |
WO2012004009A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
CA2804545A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
US20140073778A9 (en) | 2010-07-09 | 2014-03-13 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
WO2012004007A1 (en) | 2010-07-09 | 2012-01-12 | Fresenius Kabi Deutschland Gmbh | Conjugates comprising hydroxyalkyl starch and a cytotoxic agent and process for their preparation |
EP2633053A1 (en) | 2010-10-29 | 2013-09-04 | Noxxon Pharma AG | Use of hepcidin binding nucleic acids for depletion of hepcidin from the body |
CN103083680B (zh) * | 2011-11-07 | 2014-12-24 | 北京键凯科技有限公司 | 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物 |
JP5999659B2 (ja) * | 2011-12-14 | 2016-09-28 | 国立大学法人 筑波大学 | 新規分岐ポリエチレングリコール及びその用途 |
CN103965458B (zh) * | 2013-01-28 | 2017-02-15 | 天津键凯科技有限公司 | 聚乙二醇‑氨基酸寡肽‑达沙替尼结合物及其药物组合物 |
CN106146325B (zh) * | 2015-04-24 | 2019-01-29 | 北京键凯科技股份有限公司 | 一种y型多缩乙二醇衍生物及其制备方法 |
CN107446908A (zh) * | 2016-06-01 | 2017-12-08 | 湖南华腾制药有限公司 | 分支型聚乙二醇修饰的l‑门冬酰胺酶及其制备方法 |
CN108530637B (zh) * | 2017-03-05 | 2021-03-30 | 厦门赛诺邦格生物科技股份有限公司 | 一种单一功能化支化聚乙二醇的制备方法 |
CN108530642B (zh) * | 2017-11-24 | 2021-01-15 | 四川大学 | 可生物降解的三嵌段杂臂星形双亲性高分子材料及其制备方法 |
KR20230078657A (ko) | 2020-08-27 | 2023-06-02 | 에노시 테라퓨틱스 코퍼레이션 | 자가면역 질환 및 암을 치료하기 위한 방법 및 조성물 |
CN112898561A (zh) * | 2021-01-27 | 2021-06-04 | 大连理工大学 | 马来酰亚胺封端聚苯醚及其制备方法 |
WO2023198082A1 (zh) * | 2022-04-12 | 2023-10-19 | 厦门赛诺邦格生物科技股份有限公司 | 一种非线性聚乙二醇化脂质及其应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE756285A (fr) * | 1969-09-17 | 1971-03-17 | Hoechst Ag | Produits de polyoxethylation fluores utilisables pour l'appretage de textiles |
GB1361627A (en) * | 1970-08-04 | 1974-07-30 | Marumo H | Detergent composition |
IT956228B (it) * | 1972-04-15 | 1973-10-10 | Snia Viscosa | Metodo ed additivi per conferire proprieta antistatiche a composi zioni poliammidiche e prodotti poliammidici ottenuti secondo tale metodo e con l impiego di tali additivi |
US4520145A (en) * | 1982-07-21 | 1985-05-28 | The Boots Company Plc | Modified thermosetting imide resins with improved fracture toughness |
DE3730797A1 (de) | 1987-09-14 | 1989-03-23 | Siegel Rolf | Materialien mit nicht-thrombogener oberflaeche |
GB2215806B (en) | 1988-02-15 | 1992-02-05 | Hakko Co | Method of applying a lining to a pipeline |
US5122614A (en) * | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
JPH0362814A (ja) * | 1989-07-29 | 1991-03-18 | Nisshinbo Ind Inc | 親水性ポリカルボジイミドポリマー、該親水性ポリカルボジイミドポリマーによるパルプ状物及びそれらの製造方法 |
JP2902201B2 (ja) * | 1991-03-18 | 1999-06-07 | ストックハウゼン ルイジアナ リミティド | 超吸収性ポリマーの残留アクリル酸含量を低下させる方法 |
US5382657A (en) * | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5349001A (en) * | 1993-01-19 | 1994-09-20 | Enzon, Inc. | Cyclic imide thione activated polyalkylene oxides |
US5824701A (en) * | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
US5919455A (en) * | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
AU6138396A (en) * | 1995-06-26 | 1997-01-30 | Daiichi Pure Chemicals Co., Ltd. | Stable plasmin solution |
US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
SI0932399T1 (sl) * | 1996-03-12 | 2006-10-31 | Pg Txl Co Lp | Vodotopna paklitakselna predzdravila |
US6258351B1 (en) * | 1996-11-06 | 2001-07-10 | Shearwater Corporation | Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels |
CN1164533A (zh) | 1997-01-09 | 1997-11-12 | 云南汉德技术发展有限公司 | 一种水溶性抗癌化合物-聚氨基酸紫杉醇酯 |
US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
JP2003528824A (ja) | 2000-02-04 | 2003-09-30 | スプラテック ファーマ インコーポレイティド | 血管内皮成長因子受容体のためのリガンド |
CN1125097C (zh) | 2000-07-05 | 2003-10-22 | 天津大学 | 聚乙二醇支载的紫杉醇或多烯紫杉醇的前药 |
CN100475269C (zh) | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | 亲水性聚合物-谷氨酸寡肽与药物分子的结合物、包含该结合物的组合物及用途 |
DE60315145T2 (de) * | 2002-03-13 | 2008-04-30 | Beijing Jiankai Technology Co., Ltd. | Hydrophiles polymerderivat mit y-verzweigung und herstellungsverfahren dafür; obige verbindung enthaltender medizinischer verbundwerkstoff |
CN1309763C (zh) | 2002-10-31 | 2007-04-11 | 日本化药株式会社 | 喜树碱的高分子衍生物 |
-
2003
- 2003-03-12 DE DE60315145T patent/DE60315145T2/de not_active Expired - Lifetime
- 2003-03-12 US US10/507,452 patent/US8003089B2/en active Active
- 2003-03-12 CN CNB038011050A patent/CN1243779C/zh not_active Expired - Lifetime
- 2003-03-12 AU AU2003221291A patent/AU2003221291A1/en not_active Abandoned
- 2003-03-12 ES ES03709581T patent/ES2291620T3/es not_active Expired - Lifetime
- 2003-03-12 JP JP2003574704A patent/JP4272537B2/ja not_active Expired - Fee Related
- 2003-03-12 EP EP03709581A patent/EP1496076B1/en not_active Expired - Lifetime
- 2003-03-12 AT AT03709581T patent/ATE368066T1/de active
- 2003-03-12 WO PCT/CN2003/000179 patent/WO2003076490A1/zh active IP Right Grant
-
2010
- 2010-05-17 US US12/781,173 patent/US20100221213A1/en not_active Abandoned
-
2011
- 2011-06-17 US US13/163,080 patent/US20110243892A1/en not_active Abandoned
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008052428A1 (fr) * | 2006-10-24 | 2008-05-08 | Beijing Jenkem Technology Co. Ltd | Procédé de preparation et conjugué avec molécule médicinale correspondante |
CN101636414B (zh) * | 2007-09-04 | 2012-02-15 | 厦门伯赛基因转录技术有限公司 | 聚乙二醇修饰的干扰素α2b及其制备方法和应用 |
WO2014114262A1 (zh) * | 2013-01-28 | 2014-07-31 | 天津键凯科技有限公司 | 水溶性聚合物-氨基酸寡肽-药物结合物及其制备方法和用途 |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
CN104109235A (zh) * | 2014-05-30 | 2014-10-22 | 厦门赛诺邦格生物科技有限公司 | 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质 |
CN106750250A (zh) * | 2016-12-21 | 2017-05-31 | 沈阳化工大学 | 以氨基酸作为连接臂的聚乙二醇齐墩果酸衍生物及其制备方法和应用 |
CN106750250B (zh) * | 2016-12-21 | 2019-04-23 | 沈阳化工大学 | 以氨基酸作为连接臂的聚乙二醇齐墩果酸衍生物及其制备方法和应用 |
WO2018177055A1 (zh) * | 2017-03-30 | 2018-10-04 | 北京键凯科技股份有限公司 | 一种y型分支的亲水性聚合物羧酸衍生物的制备方法 |
CN108659227A (zh) * | 2017-03-30 | 2018-10-16 | 北京键凯科技股份有限公司 | 一种y型分支的亲水性聚合物羧酸衍生物的制备方法 |
US11359089B2 (en) | 2017-03-30 | 2022-06-14 | Jenkem Technology Co., Ltd. (Beijing) | Method for preparing Y-branched hydrophilic polymer carboxylic acid derivative |
CN109400868A (zh) * | 2018-11-30 | 2019-03-01 | 吉林化工学院 | 一种聚乙二醇单苯甲醚化合物的合成方法 |
CN109400868B (zh) * | 2018-11-30 | 2021-01-15 | 吉林化工学院 | 一种聚乙二醇单苯甲醚化合物的合成方法 |
Also Published As
Publication number | Publication date |
---|---|
US20110243892A1 (en) | 2011-10-06 |
US20100221213A1 (en) | 2010-09-02 |
JP2005520006A (ja) | 2005-07-07 |
EP1496076A4 (en) | 2006-06-21 |
WO2003076490A1 (fr) | 2003-09-18 |
EP1496076A1 (en) | 2005-01-12 |
US20050180946A1 (en) | 2005-08-18 |
ATE368066T1 (de) | 2007-08-15 |
WO2003076490A8 (fr) | 2004-10-28 |
CN1243779C (zh) | 2006-03-01 |
DE60315145D1 (de) | 2007-09-06 |
ES2291620T3 (es) | 2008-03-01 |
JP4272537B2 (ja) | 2009-06-03 |
EP1496076B1 (en) | 2007-07-25 |
AU2003221291A1 (en) | 2003-09-22 |
DE60315145T2 (de) | 2008-04-30 |
US8003089B2 (en) | 2011-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1556828A (zh) | 具有y形分支的亲水性聚合物衍生物、其制备方法、与药物分子的结合物以及包含该结合物的药物组合物 | |
EP1489125B1 (en) | Compound of hydrophilic polymer-polycarboxyl oligopeptide and medicines, medical composite comprising above compound and use of above compound in medicines | |
US6436386B1 (en) | Hydroxyapatite-targeting poly (ethylene glycol) and related polymers | |
EP1075282B1 (en) | Peg-lhrh analog conjugates | |
JP2013515791A (ja) | マルチアームポリエチレングリコール誘導体、マルチアームポリエチレングリコール誘導体と薬物との接合体およびゲル | |
WO2005121181A1 (fr) | Polyethyleneglycol-oligopeptides de type branchement d'arbre multipoint et leurs derives actifs et composes | |
CN100374443C (zh) | 亲水性聚合物-雷公藤提取物的结合物及其药物组合物 | |
CN101168594B (zh) | 寡肽为骨架的聚乙二醇活性衍生物、其制备方法及与药物分子的结合物 | |
BRPI0913281B1 (pt) | método de preparação de derivados de polietilenoglicol, aldeído de alta pureza | |
CN104371098B (zh) | 多分支亲水性聚合物‑异氰酸酯衍生物 | |
CN1252130C (zh) | 亲水性聚合物与丹参酮类药物的结合物以及包含该结合物的药物组合物 | |
CN1867578B (zh) | 亲水性聚合物-黄杨木提取物的结合物及其药物组合物 | |
CN100415801C (zh) | 聚乙二醇氨基酸n-内环羰酐活性衍生物及其药物键合物和凝胶 | |
CN1206257C (zh) | 亲水性聚合物-水飞蓟提取物的结合物以及包含该结合物的药物组合物 | |
CN1259314C (zh) | 亲水性聚合物-黄酮结合物以及包含该结合物的药物组合物 | |
CN109776787A (zh) | 多臂靶向偶联物 | |
CN118649242A (zh) | 两亲性树枝状多肽在肽类药物口服递送中的应用 | |
CN117531021A (zh) | 一种刺五加苷e-靶向肽偶联物及其应用 | |
CN115819641A (zh) | 一种改性硫酸软骨素及其制备方法和药物组合物 | |
CN114796240A (zh) | 一种自组装手性短肽药物及其制备方法和应用 | |
CN115869312A (zh) | 一种pdc抗肿瘤药物及其制备方法与应用 | |
JPS62263198A (ja) | 細胞保護作用を有する環状ペプチド |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JIANKAI SCIENCE AND TECHNOLOGY CO., LTD., BEIJING Free format text: FORMER OWNER: JIANKAI SCIENCE AND TECHNOLOGY CO., LTD., BEIJING Effective date: 20080815 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080815 Address after: C, building 2, international science and Technology Pioneer Park, No. four information road, Beijing, Haidian District, China: 100085 Co-patentee after: JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Patentee after: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING) Address before: C, building 2, international science and Technology Pioneer Park, No. four information road, Beijing, Haidian District, China: 100085 Patentee before: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING) |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20091202 Pledge (preservation): Pledge |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20110401 Granted publication date: 20060301 Pledgee: Bank of China Limited by Share Ltd. Beijing subbranch Pledgor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Registration number: 2009110000662 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Hydrophili polymer derirative having Y shaped branch, its preparation method, combined object with medicine molecule and medical compositon containing combined object Effective date of registration: 20110629 Granted publication date: 20060301 Pledgee: Zhongguancun Beijing science and technology Company limited by guarantee Pledgor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Registration number: 2011990000250 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20120607 Granted publication date: 20060301 Pledgee: Zhongguancun Beijing science and technology Company limited by guarantee Pledgor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Registration number: 2011990000250 |
|
CP03 | Change of name, title or address |
Address after: 100192 Beijing, Haidian District West Road, No. 66 Dongsheng science and Technology Park, building C1, floor 3 Patentee after: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING) Patentee after: JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Address before: Haidian District, Beijing, China No. 2 on the road to the international information technology park C building, level Four Patentee before: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING) Patentee before: JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) |
|
CP03 | Change of name, title or address | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20041222 Assignee: BIOSTEED GENE TRANSFORMATION TECH Co.,Ltd. Assignor: JENKEM TECHNOLOGY Co.,Ltd. (BEIJING)|JENKEM TECHNOLOGY Co.,Ltd. (TIANJIN) Contract record no.: 2017990000181 Denomination of invention: Hydrophili polymer derirative having Y shaped branch, its preparation method, combined object with medicine molecule and medical compositon containing combined object Granted publication date: 20060301 License type: Exclusive License Record date: 20170516 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060301 |